MedTrace Logo

Study of Purified Umbilical Cord Blood CD34+ Stem Cell on Chronic Ischemic Stroke

NCT01438593 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2012-08-02

No results posted yet for this study

Summary

The purpose of the study is to determine the safety and possible effectiveness of brain transplants of CD34+ stem cells obtained from umbilical cord blood (UCB) to treat stroke.

Conditions

  • Ischemic Stroke
  • Ischaemic Cerebral Infarction
  • Infarction, Middle Cerebral Artery
  • Ischemia
  • Brain Ischemia

Interventions

PROCEDURE

Intercerebral implantation of allogenic CD34+ stem cell

Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Shinn-Zong Lin, M.D.;PhD. · China Medical University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01438593 on ClinicalTrials.gov